Complex karyotypes, TET2 mutations lower survival rates
Cleveland Clinic researchers warn against overtreatment
Insurance data analysis uncovers real-world behaviors
Response in patient subgroups shows promise, however
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Screening high-risk patients early may be the way to go
Researchers suspect that mutations may be leukemogenic
Taussig Cancer Institute chair picks most significant research
Superior outcome for young adults on pediatric regimen
Combination therapy shows improved response in some
